Genzyme Rejects Bid From Sanofi-Aventis

Are Biotechs Too Cheap?


genz genzyme 300x176 Genzyme Rejects Bid From Sanofi AventisThis morning people woke up to shares of Genzyme Corp. (NASDAQ:GENZ) trading sharply higher in pre-market trading. On Sunday, Genzyme received an $18.5 billion offer from Sanofi-Aventis (NYSE:SNY) which comes to $69 per share.

The bid was rejected by the Genzyme Board despite their recent manufacturing issues. This decision could send a sign that many bio pharma stocks, including Genzyme are undervalued. We will probably see some increased volume and news flow early in the week from this sector. Especially with the mid and large cap names.

This M&A activity also bodes well for some of the unknown and under followed names on the OTCBB. Unlike most other sectors, excluding mining penny stocks, tiny microcap biotech and bio pharma stocks do get funding from larger companies from time to time.

For instance, giving a potential hot biotech penny stock $5 or $10 million dollars in R&D money is a small risk to take for a multi-billion dollar corporation looking for a new that could potentially become part of their pipeline.

While I can’t say for sure, it is probably safe to say that you will see some of the top penny stock newsletters writing about this trend in the next few weeks. Please keep in mind that the vast majority of biotech and biopharma stocks are very risky, and shouldn’t be owned by the feint of heart. However, this group has offered some investors some of the most massive gains.

So if you decide to buy one these biotech names of of a penny stock list, make sure you invest small. Also, when investing in a biotech always check their cash position and burn rate. These two numbers will tell you how much money the company has and how quickly they go through it.


 

1:11 pm | | Tags: , , | No Comments »

Will Biotech Heat Up the Penny Stock World?

Biotech Stocks To Buy?


sanofi aventis Will Biotech Heat Up the Penny Stock World?Sanofi-Aventis (NYSE-SNY) now has approval from the board of directors to offer as much as $70 per share for Genzyme (NASDAQ:GENZ).  This equals roughly $18.7 billion for the transaction. Last week we mentioned that the Biotech ETF (NYSE:BBH) was a more conservative way to take advantage of the GENZ takeover rumor.

History tells us that a high profile takeover of a company like GENZ usually spurs interest within the particular sector. This interest also can trickle down from the NYSE to the OTCBB as speculative money is getting freed up with the turn in the markets.

Volatile and super liquid bio-pharma stocks like Rexhan Pharmaceuticals (AMEX:RNN) and Neostem, Inc. (AMEX:NBS) may see increased activity as well. It has been proven that “most” start up biotech stocks don’t work in the long term. Most investors know that if they want a core biotech holding for their portfolio, they will look at companies like Amgen (NASDAQ:AMGN) or they can simply buy a biotech ETF or a sector mutual fund.  Most penny stock and small cap investors are looking for a speculative “home run”.

The potential takeover frenzy in the biotech space may or may not materialize. This is why penny stock investors and traders need to be nimble. In the next few weeks you might see constant PR’s coming from many different biotech penny stocks. Especially since commodity stocks have been beat up recently and many mining penny stocks have lost their luster recently.

The key now is finding these low priced biotech stocks. The best thing to do right now is form a penny stock list that features some different biotech names. Then look for companies with some cash and low burn rates. Then monitor news on large cap biotechs and general sector news as well. Keep in mind that this positive news cycle may not last. If it does……great, but if it doesn’t you have to be prepared to get out of the trade breakeven or at a small loss. So the best way to approach this trend might be as a trader not an investor. Remember there are penny stock flippers out there who trade these types of trends for a living. So be prepared, do your homework and remember to only commit a portion of your liquidity to an idea.

 

1:45 am | | Tags: | No Comments »

Hot Biotech Stocks like (AMEX:RPC) Primed to Rise

Radient Pharmaceuticals Corporation (AMEX:RPC)


rpc penny stock Hot Biotech Stocks like (AMEX:RPC) Primed to RiseWe hope that everyone is enjoying their summer.  We have not come out with a profile in a while because the markets have been turbulent.  We have been seeing them bounce back lately and the Dow is back over 10,500.  This is a crucial point.  There is a lot of indication that big money is coming back into the markets investors are gaining confidence.

We have seen some small cap stocks have a substantial amount of money invested into them over the past few weeks.  This is good news after we saw a huge drop off in the amount of money being invested in the small cap arena.   Most penny stocks were either stagnant or drifting lower on little volume.

We have located an AMEX company that we feel is worth putting on our radar.  RPC is a company that has had a lot of press so far this year.  They company produces and markets cancer testing products.  Back in early April RPC ran from .23 to 2.19 virtually over night.  Millionaires were literally made in a day.

We have seen a drop off in price since then.  It has found a home trading near the 1.00 level.  When a company like RPC makes an 800% plus run like it did, we usually see two events happen that cause the share price to drift lower. (1) People take profits.  If you just made that type of gain on your money you would be crazy not to take some of the winnings off of the table. (2) Shorts will come into the stock because they know that people will be taking profits and it will cause the price to decline.  They take advantage of the declining price and even help it to go lower with the additional selling pressure that is applied when a stock is shorted.

radient pharma stock chart Hot Biotech Stocks like (AMEX:RPC) Primed to Rise


This is why I love RPC.  The stock was mostly accumulated at much higher levels.  There was a period of 3 days back in April in which well over $100 million dollars worth of stock was bought.  This is a huge amount of money for a small cap company like RPC.

Any type of news from the company could allow for a huge gap up.  If you look at the chart you will see that most of the accumulation was done well above these levels.  The break even price for investors is much higher than the current levels.

Make sure that you do your own research on RPC and consult a professional to see if it is a suitable investment for you.  It has been known to be volatile in the past but at the same time it has been a huge home run for speculative investors.

We will keep you updated on RPC and periodically inform you of its progress.  You can start your research at http://finance.yahoo.com/q?s=RPC and check out the company’s new website at http://www.radient-pharma.com/.

 

11:33 am | | Tags: , | 1 Comment »